Is Enicepatide legal in Australia?

Enicepatide in Australia at a glance

Classification and note come from the Enicepatide profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.

What this means

• 01

  Enicepatide is being studied in registered clinical trials but has not received TGA marketing approval in Australia.

• 02

  Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

• 03

  Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What Enicepatide is

Roche's signaling-biased GLP-1/GIP dual agonist that produced 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2, the strongest number in its class, with Phase 3 starting in 2026.

Enicepatide came to Roche through its acquisition of Carmot Therapeutics. It is designed to favor cAMP signaling and limit receptor internalization, which the company argues sustains the drug's effect.

Mechanism: Dual GLP-1 and GIP receptor agonism biased toward cAMP signaling with reduced beta-arrestin recruitment and receptor internalization.

Regulatory history: Investigational; Phase 3 (Enith 1 and 2) starting 2026

How TGA treats this kind of product

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Enicepatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Enicepatide in other countries

Frequently asked questions

Related compounds in Australia